Cytotoxicity of AMANTADIG - a semisynthetic digitoxigenin derivative - alone and in combination with docetaxel in human hormone-refractory prostate cancer cells and its effect on Na + /K + -ATPase inhibition.

Autor: Silva IT; Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina, Florianópolis, Brazil., Munkert J; Department of Biology, Chair of Pharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany., Nolte E; Department of Urology and Pediatric Urology, University Hospital Erlangen, Erlangen, Germany., Schneider NFZ; Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina, Florianópolis, Brazil., Rocha SC; Laboratório de Bioquímica Celular, Faculdade de Bioquímica, Universidade Federal de São João del Rei, Campus Centro-Oeste Dona Lindu, Divinópolis, Brazil., Ramos ACP; Laboratório de Bioquímica Celular, Faculdade de Bioquímica, Universidade Federal de São João del Rei, Campus Centro-Oeste Dona Lindu, Divinópolis, Brazil., Kreis W; Department of Biology, Chair of Pharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany., Braga FC; Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., de Pádua RM; Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Taranto AG; Laboratório de Química Farmacêutica Medicinal, Universidade Federal de São João del Rei, Campus Centro-Oeste Dona Lindu, Divinópolis, Brazil., Cortes V; Laboratório de Bioquímica Celular, Faculdade de Bioquímica, Universidade Federal de São João del Rei, Campus Centro-Oeste Dona Lindu, Divinópolis, Brazil., Barbosa LA; Laboratório de Bioquímica Celular, Faculdade de Bioquímica, Universidade Federal de São João del Rei, Campus Centro-Oeste Dona Lindu, Divinópolis, Brazil., Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Erlangen, Germany., Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Erlangen, Germany., Simões CMO; Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina, Florianópolis, Brazil. Electronic address: claudia.simoes@ufsc.br.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2018 Nov; Vol. 107, pp. 464-474. Date of Electronic Publication: 2018 Aug 11.
DOI: 10.1016/j.biopha.2018.08.028
Abstrakt: Cardiac glycosides (CGs) are natural compounds used to treat congestive heart failure. They have garnered attention as a potential cancer treatment option, especially because they bind to Na + /K + -ATPase as a target and activate intracellular signaling pathways leading to a variety of cellular responses. In this study we evaluated AMANTADIG, a semisynthetic cardenolide derivative, for its cytotoxic activity in two human androgen-insensitive prostate carcinoma cell lines, and the potential synergistic effects with docetaxel. AMANTADIG induced cytotoxic effects in both cell lines, and a combination with docetaxel showed a moderate and strong synergism in DU145 and PC-3 cells, respectively, at concentrations considerably lower than their IC 50 values. Cell cycle analyses showed that AMANTADIG and its synergistic combination induced G2/M arrest of DU145 and PC-3 cells by modulating Cyclin B1, CDK1, p21 and, mainly, survivin expression, a promising target in cancer therapy. Furthermore, AMANTADIG presented reduced toxicity toward non-cancerous cell type (PBMC), and computational docking studies disclosed high-affinity binding to the Na + /K + -ATPase α subunit, a result that was experimentally confirmed by Na + /K + -ATPase inhibition assays. Hence, AMANTADIG inhibited Na + /K + -ATPase activity in PC-3 cells, as well as in purified pig kidney at nanomolar range. Altogether, these data highlight the potent effects of AMANTADIG in combination with docetaxel and offer important insights for the development of more effective and selective therapies against prostate cancer.
(Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: